CDKN2A and neoplasm: CDKN2A, KIT, and PTEN/PI3K/MTOR pathways had genomic alterations, while 90 patients with thymoma demonstrated a low frequency of genomic alterations, with an average of 1.8/tumor and low TMB; CDKN2A/B and TP53 gene alterations were found in 10% of cases, and one patient had amplification of the NTRK1 gene.